FDA announces six more CNPVs

FDA announced commissioner's national priority review vouchers (CNPV) for six more products Thursday, including obesity treatments orforglipron and Wegovy semaglutide.

The makers of both drugs — Eli Lilly and Co. (NYSE:LLY) for orforglipron and Novo Nordisk A/S (CSE:NOVO B; NYSE:NVO) for Wegovy — were at the White House Thursday, announcing discounts on the drugs to Medicare, Medicaid and through “TrumpRx” direct-to-patient sales. ...